FDA catalyst calendar · EN / KO
FDA dates, delivered before they move the market
PDUFA decisions, advisory committees and Phase 3 readouts — summarised and sent to your inbox, Telegram or Slack. Every date links to its source.
- Free weekly brief
- No password
- One-click unsubscribe
Coming up
- Nov2026
Merck Sharp & Dohme LLC — Pembrolizumab Phase 3 primary completion: Pembrolizumab (MK-3475) with chemoradiotherapy in MIBC (KEYNOTE-992). - Nov2026
Bristol-Myers Squibb — Deucravacitinib Phase 3 primary completion: Efficacy and safety of Deucravacitinib in adults with active Sjögren's Syndrome. - Nov2026
Han Xu, M.D., Ph.D., FAPCR, Medical Director,, IRB Chair — ETOPOSIDE - Usual Phase 3 primary completion: Pharmacogenomics ANDA SNP Clinical Study - Etoposide and Single Nucleotide Polymorphisms. - Nov2026
EMD Serono Research & Development Institute, Inc. — Avelumab Phase 3 primary completion: Avelumab Program Rollover Study. - Nov2026
Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair — Abiraterone - Usual Phase 3 primary completion: Pharmacogenomics IND Commercial SNP Clinical Study - Abiraterone and Single Nucleotide Polymorphisms. - Dec2026
Innovent Biologics (Suzhou) Co. Ltd. — IBI362 Phase 3 primary completion: IBI362 vs semaglutide in overweight or obese adults with MAFLD. - Dec2026
AskGene Pharma, Inc. — ASKB589 Phase 3 primary completion: ASKB589 with CAPOX and PD-1 inhibitor in advanced or metastatic GC/GEJ adenocarcinoma. - Dec2026
Janssen Research & Development, LLC — Cetrelimab Phase 3 primary completion: TAR-200 in combination with Cetrelimab vs chemoradiotherapy in MIBC.
What you get
A brief you can read in a minute
Every Monday at 08:00 your time: what is coming up, what was decided, and which dates moved. Built from the live calendar — this preview is real data.
EmailTelegramSlack
How it works
- We track company filings, the FDA advisory calendar and ClinicalTrials.gov every day.
- Each date is checked against its source before it is sent.
- You choose how often and where: email, Telegram or Slack.
Pricing
Free
$0
Weekly brief every Monday- Weekly brief every Monday
- Full public calendar with sources
- Email, Telegram or Slack delivery
- Calendar feed for Google / Apple Calendar
Pro
$8 / month
or $72 / year — save 25%- Everything in Free
- Daily brief and monthly outlook
- Watchlist of up to 50 tickers
- Reminders 7 days and 1 day before each date
Cancel anytime. Payments are handled by Creem.
Questions
Where do the dates come from?
Company 8-K filings on SEC EDGAR, the FDA advisory committee calendar and ClinicalTrials.gov. Dates extracted from filings are reviewed by a person before they are published, and every event links to its source.
What happens when a date changes?
The calendar is updated and the change is called out in your next brief, with the old and new date side by side.
Is this investment advice?
No. Catalyst Brief is a scheduling and information service. It does not recommend buying or selling any security.
Can I cancel Pro?
Yes, at any time from Settings. Pro stays active until the end of the period you paid for.
Never be surprised by an FDA date again
Join free. Upgrade only if you want daily briefs and reminders.